
Launch Pricing Strategy & Market Access Alignment
Build defensible launch pricing strategies aligned with payer coverage and health economics
What You Can Do
You create a comprehensive launch pricing framework that bridges clinical evidence, health economics, and commercial strategy. This skill generates competitive pricing benchmarks, payer-segmented pricing tiers with justification narratives, ICER-based value calculators, and market access risk mitigation plans—all packaged into HTA-ready dossiers and C-suite memos that reduce negotiation friction and accelerate coverage decisions across major markets.
Features
analyzes competitor positioning, reference pricing, and patient population segments to set defensible entry prices
creates market-specific pricing tiers (US, EU, UK, Japan, Australia) with tailored justification narratives for each payer type
computes ICER bands, cost-effectiveness thresholds, and budget impact analyses aligned with payer willingness-to-pay
identifies coverage barriers (HTA rejection, budget constraints, clinical uncertainty) and documents mitigation strategies
generates HTA/payer submission-ready documents with clinical evidence linkage, health economic modeling, and pricing rationale
produces executive-ready pricing recommendation with financial impact, competitor context, and risk assessment for leadership approval
Example Output
Competitive Pricing Benchmark Output:
- Oncology reference comparator: $8,500–$12,000/month
- Proposed entry price: $10,200/month (midpoint with 15% premium justified by PFS benefit)
- Market access positioning: Cost per QALY gained = $95,000 (below UK NICE threshold)
Payer-Segmented Strategy:
- US: Value-based rebate structure tied to real-world OS data
- EU: Reference-priced tier at €8,500/month with risk-sharing agreement
- UK: ICER submission package pre-populated with budget impact model
Risk Register Example:
- Risk: ICER review challenges cost-effectiveness assumption
- Mitigation: Pre-submission meeting scheduled; sensitivity analysis prepared for 20% pricing reduction scenario
What's Included
- SKILL.md instruction file with trigger conditions and step-by-step workflow:
- Competitive Pricing Benchmark Template: market comparator analysis framework with reference pricing data structure
- Payer-Segmented Pricing Strategy Workbook: market-specific pricing tiers with justification narrative prompts for US, EU, UK, Japan, Australia
- Health Economic Value Calculator Template: ICER band calculator, budget impact model skeleton, and population segment breakdown
- Market Access Risk Register: pre-populated risk categories (HTA rejection, budget constraints, clinical data gaps) with mitigation strategy framework
- Launch Pricing Dossier Template: HTA/payer submission structure with sections for clinical evidence linkage, pricing justification, and health economic modeling
Who It's For
- Pricing & Market Access Analysts — develop defensible pre-launch pricing frameworks aligned with payer expectations
- Commercial Strategy Leads — build market-segmented pricing strategies for multi-market launches
- Health Economics Professionals — structure ICER-based value arguments and budget impact models for payer submissions
- Launch Directors — create integrated pricing and market access plans that reduce coverage negotiation timelines
- Product Managers (Pharma/Biotech) — align clinical value propositions with payer reimbursement requirements early
Best For
- Pre-launch pricing strategy development (9–12 months before market entry)
- Health economic justification documents for HTA submissions and payer dossiers
- Competitive pricing benchmarking and market positioning analysis
- Multi-market pricing segmentation (US, EU, UK, Japan, Australia)
- Market access risk assessment and mitigation planning for launch readiness
- Payer negotiation preparation and value-based pricing structures
- Budget impact modeling and cost-effectiveness threshold analysis







